Muenster, Germany

Ingo Aldag

This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignees: Cilian Ag, Dermapharm Ag. Active years: 2020-2025.

USPTO Granted Patents = 3 

% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2020-2025

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Ingo Aldag: Innovator in Enzyme Technology

Introduction

Ingo Aldag is a notable inventor based in Münster, Germany. He has made significant contributions to the field of enzyme technology, particularly in the area of digestion. With a total of 3 patents to his name, Aldag's work focuses on improving digestive health through innovative enzymatic solutions.

Latest Patents

Aldag's latest patents include the use of enzymes with a wide pH activity range as medicaments for promoting digestion. This invention discloses a combination of two or more lipase enzymes aimed at treating lipid digestion deficiencies and digestive disorders. Notably, at least one lipase enzyme has a pH optimum at an acidic pH value, while at least one other lipase enzyme operates optimally at an alkaline pH value. This dual approach enhances the effectiveness of the treatment across varying digestive conditions.

Career Highlights

Ingo Aldag is currently associated with Cilian AG, where he continues to develop innovative solutions in enzyme technology. His work has garnered attention for its potential to improve digestive health and address common digestive disorders.

Collaborations

Aldag collaborates with notable colleagues, including Marcus Wolf and William Hartmann, to further advance research and development in his field.

Conclusion

Ingo Aldag's contributions to enzyme technology represent a significant advancement in promoting digestive health. His innovative patents and collaborative efforts position him as a key figure in the field of enzymatic research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…